FDA Psychiatry Division To Be Headed By Laughren Under Restructuring Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Neuropharmacological reviewer Laughren will head FDA's psychiatric drug reviews after the division is spun off under the Office of New Drugs reorganization. Laughren's appointment is one of few top-level promotions under the restructuring effort.